Your browser doesn't support javascript.
loading
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman, Rury R; Bethel, Mary Angelyn; George, Jyothis; Sourij, Harald; Doran, Zoë; Keenan, Joanne; Khurmi, Nardev S; Mentz, Robert J; Oulhaj, Abderrahim; Buse, John B; Chan, Juliana C; Iqbal, Nayyar; Kundu, Sudeep; Maggioni, Aldo P; Marso, Steven P; Öhman, Peter; Pencina, Michael J; Poulter, Neil; Porter, Lisa E; Ramachandran, Ambady; Zinman, Bernard; Hernandez, Adrian F.
Afiliação
  • Holman RR; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom. Electronic address: rury.holman@dtu.ox.ac.uk.
  • Bethel MA; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • George J; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • Sourij H; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • Doran Z; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • Keenan J; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • Khurmi NS; AstraZeneca Research and Development, Gaithersburg, MD.
  • Mentz RJ; Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.
  • Oulhaj A; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom.
  • Buse JB; University of North Carolina at Chapel Hill, School of Medicine, Chapel Hill, NC.
  • Chan JC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
  • Iqbal N; Bristol-Myers Squibb, Princeton, NJ.
  • Kundu S; Bristol-Myers Squibb, Princeton, NJ.
  • Maggioni AP; ANMCO Research Centre, Florence, Italy.
  • Marso SP; University of Texas Southwestern Medical Center, Dallas, TX.
  • Öhman P; AstraZeneca Research and Development, Gaithersburg, MD.
  • Pencina MJ; Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.
  • Poulter N; International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom.
  • Porter LE; Dance Biopharm, Inc, Brisbane, CA.
  • Ramachandran A; India Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India.
  • Zinman B; Samuel Lunenfeld Research Institute, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Hernandez AF; Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC.
Am Heart J ; 174: 103-10, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26995376
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Peptídeos / Peçonhas / Doenças Cardiovasculares / Medição de Risco / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: America do norte / Asia / Europa Idioma: En Revista: Am Heart J Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Peptídeos / Peçonhas / Doenças Cardiovasculares / Medição de Risco / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Região como assunto: America do norte / Asia / Europa Idioma: En Revista: Am Heart J Ano de publicação: 2016 Tipo de documento: Article